Biopharmaceutical researcher Vical (VICL +7%) says it will get a $130M upfront payment from...

|About: Vical Incorporated (VICL)|By:, SA News Editor

Biopharmaceutical researcher Vical (VICL +7%) says it will get a $130M upfront payment from Japan's Astellas Pharma (ALPMY.PK) in a new licensing deal to develop and sell its TransVax vaccine.